Pfizer exceeds fourth-quarter expectations but starts 2023 with low forecastBy Associated Press ReportersCovid-19 booster vaccines and treatments for coronavirus helped push Pfizer to a better-than-expected final quarter of 2022. However, the pharmaceutical giant announced on Tuesday a 2023 forecast that starts off well below Wall Street forecasts. In the recently completed fourth quarter, Pfizer booked nearly half of its 24.29 billion US dollars (£19.62 billion) in revenue from its top-selling Covid vaccine Comirnaty and another 1.8 billion dollars (£1.5 billion) from the treatment Paxlovid. Analysts had forecast fourth-quarter earnings of 1.05 dollars (85p) per share on 24.38 billion dollars (£19.69 billion) in revenue, according to FactSet. For the new year, Pfizer expects adjusted earnings to range between 3.25 dollars (£2.63) and 3.45 dollars (£2.79) per share.

Source: Irish Independent February 01, 2023 04:20 UTC